Immix Biopharma (IMMX) Income towards Parent Company (2021 - 2026)

Immix Biopharma has reported Income towards Parent Company for 6 years, with the latest figure at -$10.1 million in Q1 2026.

• Quarterly Income towards Parent Company fell 122.05% year-over-year to -$10.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$26.7 million (down 3259.47% YoY) and the FY2025 annual result came in at -$21.2 million, down 1236.49% from the prior year.
• Income towards Parent Company slipped to -$10.1 million in Q1 2026 per IMMX's latest filing, from -$2.4 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at $15.3 million in Q4 2024 and troughed at -$10.1 million in Q1 2026.
• A 5-year average of -$3.0 million and a median of -$3.6 million in 2023 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2022 and 2024: Income towards Parent Company tumbled 649.04% in 2022, then jumped 1965.89% in 2024.
• Over 5 years, Income towards Parent Company stood at -$2.1 million in 2022, then surged by 60.06% to -$820134.0 in 2023, then surged by 1965.89% to $15.3 million in 2024, then slumped by 115.77% to -$2.4 million in 2025, then sank by 317.98% to -$10.1 million in 2026.
• According to Business Quant data, Income towards Parent Company over the past three periods registered -$10.1 million, -$2.4 million, and -$7.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.